Adcock Ingram Holdings Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adcock Ingram Holdings Ltd.
Adcock Kept Cash Back For Two Major Deals, Prioritizes Partnerships
Adcock Ingram intends to continue seeking partnership deals with multinational firms, after failing to complete two significant acquisitions during its financial year ended 30 June 2022.
Blitzima A Boost For Adcock As It Scoops Up New Rituximab Patients
South Africa’s Adcock Ingram gave a sprawling update of its operations for the first half of its financial year ending in June 2022, which saw a rise in sales but a decline in profit for its Prescription business.
Adcock Ingram Breaks Into Biosimilars With Infliximab
South African firm Adcock Ingram has described the launch of Celltrion’s Remsima (infliximab) biosimilar as “a really good step for us,” as it saw volumes plunge for its Prescription business during its financial year ended 30 June.
Adcock Reports Slight Growth In A ‘Difficult Market’
Adcock has made slight progress despite the effect of the current economic climate in South Africa on consumer spending and behavior.
- Medical Devices
- Generic Drugs
- OTC, Consumer
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.